Here are the 3 things we're watching in the stock market this week

• 

  Happiness Researchers Studied 50,000 People. Here’s the Surprising Thing They Learned

  Need to schedule an important meeting or call? Timing is everything.
  
  Inc. - 3h

• Top Wall Street analysts pick these 3 stocks for attractive dividends

  TipRanks' analyst ranking service spotlights three dividend-paying stocks, including International Business Machines and Verizon.
  
  CNBC - 1d
• 

  Here’s a Look at the 3 Israeli Hostages Freed Saturday

  The release of the three men was the fifth in a staggered hostage-for-prisoner exchange laid out in a cease-fire deal between Hamas and Israel.
  
  The New York Times - 1d

• Why the stock market bulls are rooting for the Eagles in the Super Bowl

  Subjecting the Super Bowl Predictor to statistical scrutiny.
  
  MarketWatch - 17h

• Do you have too much of your money invested in the stock market?

  Also: A big warning for Tesla’s shareholders, Roth IRA timing and companies that are likely takeover targets.
  
  MarketWatch - 17h

• These 2 seasonal stock-market patterns could give your portfolio a boost

  Investors take notice of the presidential cycle and years ending in ‘5.’
  
  MarketWatch - 1d
• 

  17 things Trump and his team did this week

  In his third week back in office, Trump took action on issues from transgender competitors in women's sports to Gaza.
  
  BBC News - 1d

• Beauty stocks post major losses after a week of worrying results

  Several beauty stocks tanked this week, as companies such as E.l.f. Beauty and Estee Lauder reported disappointing earnings and cut guidance.
  
  CNBC - 2d

• Here are some of this week’s biggest stock winners and losers in the portfolio

  Every weekday, the Investing Club releases the Homestretch; an actionable afternoon update just in time for the last hour of trading.
  
  CNBC - 2d

More from CNBC

• Trump to impose 25% tariffs on steel and aluminum — here are the likely winners and losers

  Perhaps unsurprisingly, the biggest winner of the trade tariffs is likely to be the U.S.
  
  CNBC - 1h

• Trump is unlikely to end Medicare drug price talks — here's what that means for patients and pharma

  Trump could either weaken the negotiations in a way that benefits the pharmaceutical industry, or try to achieve even deeper savings to outdo his predecessor.
  
  CNBC - 36m

• McDonald’s revenue disappoints as U.S. customers spend less at its restaurants

  Shares of McDonald's have risen just 2% over the past year.
  
  CNBC - 1h

• Steel and aluminum stocks surge on Trump plan to impose 25% tariffs on imports to U.S.

  The aluminum tariff would add nearly 30 cents per pound to prices not including transportation and other costs, according to JP Morgan.
  
  CNBC - 36m

• Consumer Financial Protection Bureau staff told to 'stand down' from all work

  CFPB employees were told Sunday to work remotely because their Washington, D.C., headquarters would be closed through Feb. 14, according to a memo.
  
  CNBC - 6m

More in Business

• Consumer Financial Protection Bureau staff told to 'stand down' from all work

  CFPB employees were told Sunday to work remotely because their Washington, D.C., headquarters would be closed through Feb. 14, according to a memo.
  
  CNBC - 6m
• 

  Fox Acquires Firm Behind Conservative and True Crime Podcasts

  Tucker Carlson, Nancy Grace, Megyn Kelly and Piers Morgan are among the clients of Red Seat Ventures, which now joins Rupert Murdoch’s empire.
  
  The New York Times - 8m

• Musk calls to impeach judge whose order blocks DOGE from Treasury systems access

  Musk wants to impeach a federal judge after an order temporarily restricts his team from accessing the Treasury Department's payment systems and sensitive data.
  
  CNBC - 11m
• 

  The Best and Worst Super Bowl Commercials, Ranked

  Here is our critic’s survey of this year’s Super Bowl commercials, from best to worst.
  
  The New York Times - 23m

• Trump is unlikely to end Medicare drug price talks — here's what that means for patients and pharma

  Trump could either weaken the negotiations in a way that benefits the pharmaceutical industry, or try to achieve even deeper savings to outdo his predecessor.
  
  CNBC - 36m